New Biomarker Technique Could Provide Early Detection for Cancer

May 19, 2010, University of Connecticut
Professor Rusling, left, with graduate students Bhaskara Chikkaveeraiah, center, and Ruchika Malhotra in their lab in the Chemistry Building. Photo by Jessica Tommaselli

( -- UConn researchers are developing techniques to detect biomarker proteins that can indicate the presence of cancer before symptoms are apparent.

Modern can predict your risk of contracting particular diseases based on predispositions discovered in your DNA. But what if similar biotechnology could tell you that you’ve got a disease before you notice any symptoms? What if it could even tell you, before any signs of a tumor, that you have cancer?

Jim Rusling, professor of chemistry at UConn and professor of cell biology at the UConn Health Center, ponders these questions on a daily basis. Since 2006, he and colleagues at the University and the National Institutes of Health (NIH) have been developing techniques to detect biomarker proteins - the physiological traits that indicate that a person has a specific disease - for prostate and oral cancer. Because these biomarkers are often present in the blood in a disease’s early stages, they can be used for early detection and prevention.

“DNA predicts which proteins can be made, but it can’t predict which proteins are actively expressed,” Rusling says. “It only assesses the risk of a disease. There’s a big push now to measure proteins as biomarkers.”

In a recent publication in the journal Analytical Chemistry, Rusling and his colleagues describe a system they developed to detect with record sensitivity the levels of a associated with several types of oral cancer, including head and neck squamous . The project was funded by a $1.5 million grant from the National Institute of Environmental Health Sciences at NIH.

The protein, called interleukin-6 or IL-6, is normally present in very low levels in the bloodstream - so low that previous biomarker sensors might not be able to detect it. This and other biomarkers are signaling molecules, which can instruct cells that have become cancerous to grow faster. Their levels can increase even before tumors begin to form, enabling early detection that might head off the formation of cancerous growths.

In their paper, Rusling, UConn graduate student Ruchika Malhotra, and colleagues Vyomesh Patel, Jose Pedro Vaqué, and Silvio Gutkind of NIH report the development of a new sensor, in which a cluster - or as the researchers call it, a “forest” - of densely packed nanoscale carbon tubes was exposed to a patient’s serum. Several steps, including introducing antibodies, other nanotubes, and the patient’s serum itself, resulted in the IL-6 proteins getting caught between two of the carbon nanotubes.

The researchers then applied an electrical current to the forest, and enzyme-labeled tubes that had captured IL-6 proteins produced an electrical signal. This method, says Rusling, can detect the lowest levels of IL-6 in the blood, which is less than a trillionth of a gram in one fluid ounce of patient serum.

“The electronics is simple: people have known for 200 years that when you apply a voltage to a metal, you get a current,” Rusling says. “Now we’re adapting this approach to microfluidic systems that measure proteins.”

The researchers chose IL-6 specifically because of its unusually low normal levels; they wanted to be sure that their technique could accurately identify trace proteins. This gives the researchers a baseline with which to compare the elevated levels observed in people’s blood just before they develop cancer.

The exciting thing about biomarker techniques such as this one, says Rusling, is that they can be applied to any cancer. Since many biomarkers are common to more than one cancer, he hopes that a panel of these types of assays could detect the markers of the world’s most common and worst cancers.

Currently, instruments that can perform these tests exist in some laboratories, but the commercially-available versions have yet to make it to clinical practices, partly because they’re still very expensive and technically demanding. But they also don’t yet have a useful clinical output, which is a key for clinicians. Testing for five to 10 common biomarkers could lead to a 99 percent accurate predication rate for cancers, Rusling says, but the risk of false positives and negatives needs to be sufficiently low to convince doctors to use the techniques.

“Suppose you measure eight for ,” he says. “How do you take that data and make it into one number that a clinician can trust and interpret?”

The next stage is to create an automated system that can perform all these steps within a simple, small, point-of-care device, says Rusling. Currently, blood samples and antibodies need to be specially prepared and fed manually into the group’s testing setup. He envisions that in clinics, an automated tester about the size of a cell phone could accept a sample of a person’s blood, analyze the sample, and read out the results.

Rusling hopes that this proof-of-concept project will help stimulate collaborations from engineers and commercial enterprises willing to work on creating an automated tester. These testers could make early detection much easier, he says, which could go a long way toward saving lives.

“There’s not going to be one cure for cancer, because cancer is thousands of diseases,” he says. “The best thing for patients is early detection. Biomarker proteins could become the standard of early detection and treatment monitoring in the future.”

Explore further: A faster, simpler test for disease biomarkers

More information: Journal paper:

Related Stories

A faster, simpler test for disease biomarkers

December 17, 2007

In an advance toward earlier diagnosis of cancer and other disorders, scientists are reporting development of a potentially fast, simple and inexpensive blood test to detect disease “biomarkers.” The study is scheduled ...

New biomarkers for predicting the spread of colon cancer

January 13, 2010

Scientists in China are reporting discovery of two proteins present in the blood, of people with colon cancer that may serve as the potential biomarkers for accurately predicting whether the disease will spread. Their study ...

Recommended for you

Designing the next generation of hair dyes

January 17, 2018

North Carolina State University researchers have created the largest publicly available chemical database of hair dye substances as a resource for developing a new generation of hair color products that are safer for consumers, ...

Pigments in oil paintings linked to artwork degradation

January 17, 2018

Experts have long known that as oil paintings age, soaps can form within the paint, degrading the appearance of the artworks. The process significantly complicates the preservation of oil paintings—and cultural manifestations, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.